MyMD Pharmaceuticals Board Changes
Ticker: QCLS · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Mymd Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, executive-compensation
TL;DR
MyMD Pharma director Dr. Cohen out, check officer pay.
AI Summary
MyMD Pharmaceuticals, Inc. announced on April 15, 2024, a change in its board of directors. Specifically, Dr. Jonathan L. Cohen has resigned from his position as a director. The company also reported on compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes and executive compensation disclosures can sometimes indicate underlying issues or strategic shifts that may affect the company's future prospects.
Key Players & Entities
- MyMD Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jonathan L. Cohen (person) — Resigned Director
- April 15, 2024 (date) — Date of earliest event reported
FAQ
Who is Dr. Jonathan L. Cohen and what was his role prior to resignation?
Dr. Jonathan L. Cohen was a director of MyMD Pharmaceuticals, Inc. prior to his resignation on April 15, 2024.
What is the exact date of the earliest event reported in this filing?
The earliest event reported in this filing occurred on April 15, 2024.
What specific items are being reported in this 8-K filing?
This 8-K filing reports on the departure of a director, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What was the former name of MyMD Pharmaceuticals, Inc.?
MyMD Pharmaceuticals, Inc. was formerly known as Akers Biosciences, Inc.
Where is MyMD Pharmaceuticals, Inc. headquartered?
MyMD Pharmaceuticals, Inc. is headquartered at 855 N. Wolfe Street, Suite 601, Baltimore, MD 21205.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-04-18 16:30:33
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share MYMD The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 32KB
- 0001493152-24-015199.txt ( ) — 202KB
- mymd-20240415.xsd (EX-101.SCH) — 3KB
- mymd-20240415_lab.xml (EX-101.LAB) — 33KB
- mymd-20240415_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYMD PHARMACEUTICALS, INC. Date: April 18, 2024 By: /s/ Christopher Chapman, M.D. Christopher Chapman, M.D. President and Chief Medical Officer